• One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation

  • 2023/06/09
  • 再生時間： 1 時間 12 分
  • ポッドキャスト

One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:

    • The high incidence of lung cancer here in Manchester
    • The differences between non-small cell and small-cell lung cancer
    • Oncogenic drivers in lung cancer such as the KRAS mutation
    • His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE

    Colin Lindsay's research profile

    EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells

    KRAS: Reasons for optimism in lung cancer

    On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

    Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    Molecular characterization of primary and secondary resistance to RET inhibitors in patients

    with advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext
    続きを読む 一部表示

あらすじ・解説

In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:

  • The high incidence of lung cancer here in Manchester
  • The differences between non-small cell and small-cell lung cancer
  • Oncogenic drivers in lung cancer such as the KRAS mutation
  • His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE

Colin Lindsay's research profile

EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells

KRAS: Reasons for optimism in lung cancer

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Molecular characterization of primary and secondary resistance to RET inhibitors in patients

with advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext
続きを読む 一部表示

One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutationに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。